Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
SYT2 antisense RNA 1 (SYT2-AS1, also known as RP11-569A11.1) is a long non-coding RNA transcribed antisense to the SYT2 gene. Antisense lncRNAs like SYT2-AS1 typically function at the RNA level rather than encoding proteins and have roles in the regulation of their sense (protein-coding) gene partners. These functions may include regulation of gene expression, chromatin state, or alternative splicing. There is currently no evidence that SYT2-AS1 is a therapeutic target, biomarker, or directly associated with human disease, but its biological significance may relate to the post-transcriptional or epigenetic modulation of SYT2, which is essential for synaptic vesicle exocytosis in neural tissues[5][2][6].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on SYT2 antisense RNA 1 (SYT2-AS1).